Fate Therapeutics, Inc.
Every calculator, already run for FATE
Open the full toolkit →You have the numbers on FATE. Get the argument.
A written report on which of these readings actually decide the outcome for Fate Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
11 analysts covering FATEAnalyst Price Target Disagreement for Fate Therapeutics, Inc.
Wall Street's bull case implies +240% from the current price; the bear case implies -6%. A 247% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for FATE
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Fate Therapeutics, Inc.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-der…
FATE — frequently asked
Is FATE a buy right now?
Wall Street's consensus rating on Fate Therapeutics, Inc. is Buy across 11 analysts, with a mean price target of $5.74 (+144% vs. the current $2.35). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is FATE's next earnings date?
Fate Therapeutics, Inc. is next scheduled to report earnings around Nov 12, 2026. A full FATE research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Fate Therapeutics, Inc.?
Analysts covering Fate Therapeutics, Inc. (FATE) range from a bear-case target of $2.20 to a bull-case high of $8.00, with a mean consensus target of $5.74 across 9 analysts. The spread of $5.80 (247% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Fate Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Fate Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full FATE research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Fate Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.